A UCSF pilot study finds psilocybin therapy surprises, showing meaningful improvements in mood, cognition, and motor symptoms. A first-of-its-kind study tested the safety of psilocybin on patients with mild to moderate Parkinson’s disease and found that patients experienced clinically significant improvements in mood, cognition, and motor function that lasted for weeks after the drug was out of their systems.
Graduate students present research about how to track down HIV, fight brain tumors with T cells, and treat brain disorders prenatally. Ten UCSF graduate students presented their research in accessible, 3-minute talks at the 2025 Grad Slam event. This year’s first-place talk was by Sophia Miliotis on how our immune system uses matchmaking skills to look for signs of viruses in cells that should be destroyed.
A study followed the sleep patterns of older female participants to see if specific patterns of change were associated with a higher risk of dementia. The participants, whose average age was 83, were monitored by wrist devices that track movement and time spent asleep.
Research funded by the National Institutes of Health transforms patient care and buoys the Bay Area’s innovation economy. UCSF received $815 million in awards from the National Institutes of Health (NIH) last year for research that will improve the lives of patients in the U.S. and around the world.
This year’s recipients of the Bowes Biomedical Investigator Award forge unconventional paths where neurodegenerative disease and neuropsychiatry disease overlap. Martin Kampmann, PhD, and Anna Victoria Molofsky, MD, PhD, are the 2025 recipients of the Bowes Biomedical Investigator award, which supports scientists who take novel approaches and have the potential to make significant contributions to biomedicine. Recipients receive $1.25 million over five years.
A study of artificial human and chimpanzee nerve cells revealed how faster-evolving DNA gives neurons the ability to build increasingly complex brain power. How did humans evolve brains capable of complex language, civilization, and more? Scientists at UC San Francisco recently found that parts of our chromosomes have evolved at breakneck speeds to give us an edge in brain development compared to apes.
FDA approves algorithm developed by UCSF researcher that provides calibrated electrical pulses to fend off stiffness and involuntary movements before they arise. The FDA has approved an adaptive deep brain stimulation (aDBS) treatment for people with with Parkinson’s disease, making this groundbreaking technology available to people nationwide.
UCSF scientists find a trove of new targets for cancer immunotherapy in cancer’s unique version of RNA splicing. UCSF scientists have found that some cancers, like brain cancer, make unique, jumbled proteins that make them stand out. These newly recognized cancer-specific proteins, or antigens, could speed the development of potent immunotherapies that recognize and attack hard-to-treat tumors.
UCSF-led study calls for new recommendations and supplements for older adults that may offer better brain protection. A study found that B12 requirements may be too low for some people, putting them at risk for cognitive decline.
This research is among the first to show neurodegenerative diseases like Parkinson’s Disease aren’t all about your genes. Your environment matters. A new EPA ban on TCE, a common industrial cleaning agent and contaminant, begins this year. UCSF’s Samuel Goldman, who led groundbreaking research to link TCE to Parkinson’s Disease, talks about the health risks.